Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Teduglutide

14 records for Teduglutide, of which 3 are published trials.

Showing 0 records on this page

Records

14 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
TED-PAEDIATRICTeduglutidePhase 3ReportedSingle-arm open-label592020Moderate
TED-PAEDIATRIC-REGIONAL-CNprogramme recordTeduglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2020Very low
TED-PAEDIATRIC-BODY-COMPprogramme recordTeduglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2020Very low
TED-PAEDIATRIC-REGIONAL-JPprogramme recordTeduglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2020Very low
STEPS-2TeduglutidePhase 3ReportedSingle-arm open-label882013Moderate
STEPS-2-ELDERLYprogramme recordTeduglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2013Very low
STEPS-2-OLEprogramme recordTeduglutidePhase 3ReportedSingle-arm open-label—2013Very low
STEPS-2-ADHERENCEprogramme recordTeduglutidePhase 3ReportedObservational—2013Very low
STEPS-2-BIOMARKERprogramme recordTeduglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2013Very low
STEPSTeduglutidePhase 3ReportedRandomised, double-blind, placebo-controlled862012Moderate
STEPS-DDIprogramme recordTeduglutidePhase 1ReportedRandomised crossover—2012Very low
STEPS-HEPATIC-IMPprogramme recordTeduglutidePhase 1ReportedPhase 1 ascending dose—2012Very low
STEPS-RENAL-IMPprogramme recordTeduglutidePhase 1ReportedPhase 1 ascending dose—2012Very low
STEPS-PKprogramme recordTeduglutidePhase 1ReportedPhase 1 ascending dose—2012Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.